利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.013 秒)

    Detection and determination of the stages of coronary artery disease
    1.
    发明授权
    Detection and determination of the stages of coronary artery disease 有权
    检测和确定冠状动脉疾病的阶段

    公开(公告)号：US06309888B1

    公开(公告)日：2001-10-30

    申请号：US09148158

    申请日：1998-09-04

    申请人： Paul N. Holvoet ,  Désiré J. Collen

    发明人： Paul N. Holvoet ,  Désiré J. Collen

    IPC分类号： G01N3392

    CPC分类号： G01N33/721 ,  G01N33/6893 ,  G01N33/92 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  Y10S435/967 ,  Y10S435/973 ,  Y10S436/809 ,  Y10S436/819 ,  Y10T436/104165 ,  Y10T436/105831

    摘要： A method having clinically sufficient degree of diagnostic accuracy for detecting the presence of coronary artery disease in a human patient from the general population and for distinguishing between the stages of the disease in that patient is disclosed. The stages are, first, the non-acute stage, which is either asymptomatic coronary artery disease or stable angina, second, the acute stage known as unstable angina, and, third, the acute stage known as acute myocardial infarction. The diseased state (as opposed to the non-diseased state) is indicated by the clinically significant presence of a first marker in a sample from the patient. The presence of one of the two acute stages, unstable angina or acute myocardial infarction, is indicated by the clinically significant presence of a second marker in a sample from the patient. The presence of the more severe acute stage known as acute myocardial infarction is indicated by the clinically significant presence of a third marker in a sample from the patient. Preferably the first marker comprises OxLDL, the second marker comprises MDA-modified LDL, and the third marker is a troponin. Preferably the OxLDL and MDA-modified LDL are detected using monoclonal antibodies that can detect the presence of those markers in undiluted human plasma at concentrations as low as 0.02 milligrams/deciliter.

    摘要翻译： 公开了一种具有临床足够程度的诊断准确度的方法，其用于检测来自一般群体的人类患者中冠状动脉疾病的存在并区分该患者的疾病阶段。 这些阶段首先是非急性期，无论是无症状的冠状动脉疾病还是稳定型心绞痛，其次是称为不稳定性心绞痛的急性期，第三，称为急性心肌梗死的急性期。 疾病状态（与非患病状态相反）由来自患者的样品中的第一标记物的临床显着存在表示。 两个急性期之一，不稳定性心绞痛或急性心肌梗死的存在，由来自患者的样品中的第二标志物的临床显着存在表示。 称为急性心肌梗塞的更严重急性期的存在由来自患者的样品中第三个标志物的临床显着存在表示。 优选地，第一标记包含OxLDL，第二标记包含MDA修饰的LDL，第三标记是肌钙蛋白。 优选使用可以以低至0.02毫克/分升浓度的浓度检​​测未稀释的人血浆中那些标记物的存在的单克隆抗体来检测OxLDL和MDA修饰的LDL。

    Functional assay of high-density lipoprotein
    2.
    发明授权
    Functional assay of high-density lipoprotein 失效
    高密度脂蛋白的功能测定

    公开(公告)号：US06596544B1

    公开(公告)日：2003-07-22

    申请号：US09541468

    申请日：2000-03-31

    申请人： Alan M. Fogelman ,  Mohamad Navab ,  Susan Hama

    发明人： Alan M. Fogelman ,  Mohamad Navab ,  Susan Hama

    IPC分类号： G01N3392

    CPC分类号： G01N33/573 ,  A61K48/00 ,  C12Q1/42 ,  G01N33/92 ,  G01N2500/10 ,  G01N2800/044 ,  Y10T436/24

    摘要： This invention provides novel assays that are prognostic and/or diagnostic for atherosclerosis or risk of atherosclerosis. It was discovered that high density lipoprotein (HDL) or components thereof can prevent the oxidation of lipids (e.g. lipids present in LDLs) and can also repair (reduce) already oxidized lipids and thereby reduce the inflammatory response associated with and characteristic of atherosclerotic plaque formation. Moreover it was a discovery of this invention that individuals vary in the ability of their HDL to afford such protection. Thus an assay of HDL protective and/or repair activity provides a highly effective assay for risk of atherosclerosis and its associated pathologies and such assays are provided herein.

    摘要翻译： 本发明提供对动脉粥样硬化或动脉粥样硬化风险的预后和/或诊断的新型测定。 发现高密度脂蛋白（HDL）或其组分可以防止脂质（例如存在于LDL中的脂质）的氧化，并且还可以修复（减少）已经氧化的脂质，从而减少与动脉粥样硬化斑块形成相关的特征和炎性反应 。 此外，本发明的发现是，个体HDL提供这种保护的能力各不相同。 因此，HDL保护和/或修复活性的测定提供了对动脉粥样硬化及其相关病理学的风险的高效测定，并且本文提供了此类测定。

    Determination of corticosteroids in human plasma using micromass LC/MS/MS
    3.
    发明授权
    Determination of corticosteroids in human plasma using micromass LC/MS/MS 有权
    使用微质LC / MS / MS测定人血浆中的皮质类固醇

    公开(公告)号：US06541263B2

    公开(公告)日：2003-04-01

    申请号：US09788353

    申请日：2001-02-21

    申请人： Feng Gao

    发明人： Feng Gao

    IPC分类号： G01N3392

    CPC分类号： G01N33/743 ,  G01N30/7233 ,  G01N33/48714 ,  Y10T436/14 ,  Y10T436/153333 ,  Y10T436/21 ,  Y10T436/24

    摘要： The present invention is directed to a method of detecting a corticosteroid in a sample by adding an internal standard to a sample suspected of containing a corticosteroid; removing interfering compounds from the sample; placing the sample on an HPLC column equilibrated with a NH4OAc:MeOH solution and collecting an eluent; and analyzing the eluent of the HPLC column with a MS, wherein if contained in the sample, the corticosteroid forms an adduct that is detected by the MS.

    摘要翻译： 本发明涉及通过向怀疑含有皮质类固醇的样品添加内标而检测样品中皮质类固醇的方法; 从样品中除去干扰化合物; 将样品置于用NH 4 OAc·MeOH溶液平衡的HPLC柱上并收集洗脱剂; 并用MS分析HPLC柱的洗脱液，其中如果包含在样品中，皮质类固醇形成由MS检测的加合物。

    Direct serum lipids assays for evaluation of disease states
    5.
    发明授权
    Direct serum lipids assays for evaluation of disease states 失效
    用于评估疾病状态的直接血清脂质测定

    公开(公告)号：US06737275B2

    公开(公告)日：2004-05-18

    申请号：US10068305

    申请日：2002-02-05

    申请人： Neil Purdie ,  Justin A. Krouse ,  Joe Studer ,  Adrian D. Marais

    发明人： Neil Purdie ,  Justin A. Krouse ,  Joe Studer ,  Adrian D. Marais

    IPC分类号： G01N3392

    CPC分类号： G01N33/92 ,  G01N2800/044

    摘要： The invention presents a method designed to simultaneously measure certain unsaturated lipids and certain vitamins present either as single substances or in complex mixtures such as exist in serum and natural oils. Target lipids are free cholesterol, unsaturated cholesteryl esters; free polyunsaturated fatty acids, and their esters as triglycerides, and phospholipids. Distributions of these analytes over the broad range of serum lipoproteins from chylomicrons to high density fractions are determined using a procedure that involves a single step reaction in which the molecular unsaturations are subjected to non-enzymatic color inducing reagents. For natural oils and vitamins, the same method serves as a quality control procedure. Analytical detection is achieved using broad spectrum absorbance and/or fluorescence measurements. Measured spectra are aggregates of the absorbance contributions from each of the analytes. Data analyses follow two paths. One uses raw spectral data. In the other, multivariate methods of analysis, particularly principal component (or factor) analysis, leads to 2-D and 3-D clustering correlations which have significant diagnostics capabilities for the early detection of human serum disorders and for quality control.

    摘要翻译： 本发明提供了一种设计用于同时测量某些不饱和脂质和作为单一物质存在的某些维生素或者存在于血清和天然油中的复杂混合物中的方法。 目标脂质是游离胆固醇，不饱和胆固醇酯; 游离多不饱和脂肪酸及其作为甘油三酯的酯和磷脂。 使用涉及分子不饱和度经受非酶促诱导试剂的单步反应的程序来测定这些分析物在从乳糜微粒到高密度级分的血清脂蛋白的范围内的分布。 对于天然油和维生素，相同的方法用作质量控制程序。 使用广谱吸光度和/或荧光测量实现分析检测。 测量光谱是每种分析物的吸光度贡献的聚集。 数据分析遵循两条路径。 一个使用原始光谱数据。 另一方面，多变量分析方法，特别是主成分（或因子）分析导致二维和三维聚类相关性，其具有早期检测人类血清障碍和质量控制的显着诊断能力。

    Methods for providing personalized lipoprotein-based risk assessments
    6.
    发明授权
    Methods for providing personalized lipoprotein-based risk assessments 有权
    提供个性化的基于脂蛋白的风险评估方法

    公开(公告)号：US06653140B2

    公开(公告)日：2003-11-25

    申请号：US10294262

    申请日：2002-11-14

    申请人： James D. Otvos

    发明人： James D. Otvos

    IPC分类号： G01N3392

    CPC分类号： G01N33/92 ,  G01N2800/324 ,  Y10T436/104165 ,  Y10T436/106664 ,  Y10T436/24

    摘要： Methods for assessing a patient's risk of having or developing coronary heart disease based on lipoprotein measurements measure and identify values for lipoprotein subclass constituents and analyze according to predetermined test criteria to identify when there is an increased and/or decreased risk of having and/or developing coronary heart disease associated wit the measured lipoprotein subclass constituent values.

    摘要翻译： 用于评估基于脂蛋白测量的患者患有或发展冠心病的风险的方法测量和鉴定脂蛋白亚类成分的值并根据预定的测试标准进行分析以鉴定何时存在和/或发展的风险增加和/或降低 与测量的脂蛋白亚类成分值相关的冠心病。

    Method and apparatus for imaging and documenting fingerprints
    8.
    发明授权
    Method and apparatus for imaging and documenting fingerprints 失效
    用于成像和记录指纹的方法和装置

    公开(公告)号：US06485981B1

    公开(公告)日：2002-11-26

    申请号：US09362517

    申请日：1999-07-28

    申请人： Salvador M. Fernandez

    发明人： Salvador M. Fernandez

    IPC分类号： G01N3392

    CPC分类号： G01N33/92

    摘要： The invention relates to a method and apparatus for imaging and documenting fingerprints. A fluorescent dye brought in intimate proximity with the lipid residues of a latent fingerprint is caused to fluoresce on exposure to light energy. The resulting fluorescing image may be recorded photographically.

    摘要翻译： 本发明涉及一种用于成像和记录指纹的方法和装置。 导致与潜在指纹的脂质残留紧密接近的荧光染料在暴露于光能时发荧光。 所得到的荧光图像可以照相地记录。